|
 |
Paratek Pharmaceuticals seeks to maintain a dominant patent position in our
technology programs through broad protection of our proprietary compounds and
technology. Paratek's policy is to diligently protect our assays, organic
synthetic processes, lead compounds, and certain other technologies by, among
other things, filing patent applications for technology relating to the
development of our business in the United States and worldwide.
As of June 2006, the Paratek patent portfolio is as follows:
|
|
Tetracycline (TET) Program
|
MAR Program
|
|
|
U.S.
|
International
|
U.S.
|
International
|
|
Issued
|
26
|
95
|
12 |
14
|
|
Pending
|
58 |
158 |
10 |
27 |
|
Total
|
84 |
253 |
22 |
41 |
|
|
